Can epigenetic drugs prime prostate tumors for immune attack before surgery?
NCT ID NCT06888102
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether giving epigenetic therapy before prostate removal can make the cancer more visible to the immune system. About 20 men with high-risk prostate cancer will receive the drugs before their scheduled prostatectomy. The main goals are to check safety, see if the treatment delays surgery, and measure changes in gene activity in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
epigenetic therapy (drugs that change gene activity to help the immune system attack cancer)
What this could lead to
If it works, this could point toward a new way to make prostate cancer more sensitive to the immune system before surgery.
What could go wrong
This is a very early, small trial (20 men) focused on safety and feasibility, not effectiveness. The drugs may cause side effects or not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Cancer at SOCC
RECRUITINGLos Angeles, California, 90048, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact